Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class (Ascending) Administration Route Package Effective Date Package Discontinuation Date Status
69097-0313-37 69097-0313 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
69097-0314-42 69097-0314 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
69097-0805-40 69097-0805 Azacitidine Azacitidine For 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 26, 2019 In Use
71288-0108-06 71288-0108 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 26, 2020 In Use
75834-0190-01 75834-0190 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 17, 2020 In Use
64842-0727-09 64842-0727 CEDAZURIDINE and DECITABINE INQOVI 100.0 mg/1, 35.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog + CDA Inhibitor Oral Aug. 25, 2020 In Use
55513-0710-01 55513-0710 Denosumab Prolia 60.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous June 5, 2010 In Use
55513-0710-21 55513-0710 Denosumab Prolia 60.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous March 5, 2024 In Use
55513-0730-01 55513-0730 Denosumab XGEVA 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Nov. 18, 2010 In Use
72064-0210-12 72064-0210 pralsetinib GAVRETO 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sept. 4, 2020 April 30, 2022 No Longer Used

Found 10,000 results in 11 milliseconds — Export these results